Harm Reduction
Harm reduction has moved from the margins to the center of US addiction policy following the 2022 federal endorsement of syringe services and OTC naloxone (Narcan, RiVive) approval. WCAM 2027 will examine the New York City and Rhode Island overdose prevention center evaluations, fentanyl and xylazine test strip distribution under updated state paraphernalia laws, and drug checking services using FTIR spectrometry. The track will also cover safer supply pilots in British Columbia, take-home naloxone saturation modeling, the role of community health workers in post-overdose outreach, and the evidence base for medicalized supervised consumption.
- OTC naloxone (Narcan, RiVive) and community distribution saturation
- Overdose prevention centers: NYC and Rhode Island evaluation data
- Fentanyl and xylazine test strips: legality and field utility
- Drug checking with FTIR and mass spectrometry at music festivals
- Safer supply pilots: British Columbia hydromorphone programs
- Syringe services programs: HIV/HCV prevention and linkage to care
- Post-overdose outreach teams and peer-led engagement models
Explore the full WCAM 2027 program
- 01Opioid Use Disorder
- 02Alcohol Use Disorder
- 03Stimulants & Polysubstance Use
- 04Behavioral Addictions
- 06Medication-Assisted Treatment
- 07Recovery Support Services
- 08Prevention & Early Intervention
- 09Neuroscience of Addiction
- 10Trauma & PTSD-Related Use
- 11Adolescent Addiction
- 12Pregnancy & Addiction
- 13Co-occurring Mental Illness
- 14Tobacco & Nicotine Cessation
- 15Cannabis Use Disorder
- 16Psychedelic-Assisted Therapy
- 17Digital Therapeutics in Addiction
- 18Addiction Policy & Public Health
- 19Methadone & Buprenorphine Programs
- 20Naloxone & Overdose Prevention
- 21Recovery Housing
- 22Peer Support Specialists
- 23Addiction Medicine Training
- 24Stigma & Communication
- 25Drug Policy Reform
- 26International Drug Trends
- 27Older Adults & Addiction
- 28Veterans & Addiction
- 29Criminal Justice & Treatment
- 30Family Therapy
- 31Spirituality & Recovery
- 32Genetics of Addiction
- 33Polysubstance Use Trends
- 34Emerging Drugs of Abuse
- 35Workforce Development